184 related articles for article (PubMed ID: 36316485)
1. A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy.
Quijano-Rubio A; Bhuiyan AM; Yang H; Leung I; Bello E; Ali LR; Zhangxu K; Perkins J; Chun JH; Wang W; Lajoie MJ; Ravichandran R; Kuo YH; Dougan SK; Riddell SR; Spangler JB; Dougan M; Silva DA; Baker D
Nat Biotechnol; 2023 Apr; 41(4):532-540. PubMed ID: 36316485
[TBL] [Abstract][Full Text] [Related]
2. INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses.
Sulzmaier FJ; Kern N; Ahn SJ; Polovina A; Ho J; Hussain A; Cyprus G; Macedo C; Pandit R; Crago W; Rowell E; Timmer JC; Eckelman BP
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36653071
[TBL] [Abstract][Full Text] [Related]
3. Targeted chain-exchange-mediated reconstitution of a split type-I cytokine for conditional immunotherapy.
Vasic V; Buldun C; Ritz M; Dickopf S; Georges GJ; Spick C; Peuker A; Meier T; Mayer K; Brinkmann U
MAbs; 2023; 15(1):2245111. PubMed ID: 37608616
[TBL] [Abstract][Full Text] [Related]
4. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
Zhang L; Davies JS; Serna C; Yu Z; Restifo NP; Rosenberg SA; Morgan RA; Hinrichs CS
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959727
[TBL] [Abstract][Full Text] [Related]
5. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
[TBL] [Abstract][Full Text] [Related]
6. Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy.
Zhang Y; Zhuang Q; Wang F; Zhang C; Xu C; Gu A; Zhong WH; Hu Y; Zhong X
J Transl Med; 2022 Sep; 20(1):432. PubMed ID: 36167591
[TBL] [Abstract][Full Text] [Related]
7. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
[TBL] [Abstract][Full Text] [Related]
8. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
9. Immunocytokines: a new approach to immunotherapy of melanoma.
Reisfeld RA; Becker JC; Gillies SD
Melanoma Res; 1997 Aug; 7 Suppl 2():S99-106. PubMed ID: 9578424
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression.
Nirschl CJ; Brodkin HR; Hicklin DJ; Ismail N; Morris K; Seidel-Dugan C; Steiner P; Steuert Z; Sullivan JM; Tyagi E; Winston WM; Salmeron A
Cancer Immunol Res; 2022 May; 10(5):581-596. PubMed ID: 35286392
[TBL] [Abstract][Full Text] [Related]
11. A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2.
Chen X; Ai X; Wu C; Wang H; Zeng G; Yang P; Liu G
Cell Death Dis; 2018 Sep; 9(10):989. PubMed ID: 30250191
[TBL] [Abstract][Full Text] [Related]
12. Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate.
Merchant R; Galligan C; Munegowda MA; Pearce LB; Lloyd P; Smith P; Merchant F; To MD
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058325
[TBL] [Abstract][Full Text] [Related]
13. Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.
Kwong B; Gai SA; Elkhader J; Wittrup KD; Irvine DJ
Cancer Res; 2013 Mar; 73(5):1547-58. PubMed ID: 23436794
[TBL] [Abstract][Full Text] [Related]
14. Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy.
Momin N; Mehta NK; Bennett NR; Ma L; Palmeri JR; Chinn MM; Lutz EA; Kang B; Irvine DJ; Spranger S; Wittrup KD
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243150
[TBL] [Abstract][Full Text] [Related]
15. TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
Rosen DB; Kvarnhammar AM; Laufer B; Knappe T; Karlsson JJ; Hong E; Lee YC; Thakar D; Zúñiga LA; Bang K; Sabharwal SS; Uppal K; Olling JD; Kjaergaard K; Kurpiers T; Schnabel M; Reich D; Glock P; Zettler J; Krusch M; Bernhard A; Heinig S; Konjik V; Wegge T; Hehn Y; Killian S; Viet L; Runz J; Faltinger F; Tabrizi M; Abel KL; Breinholt VM; Singel SM; Sprogøe K; Punnonen J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35817480
[TBL] [Abstract][Full Text] [Related]
16. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
17. ZEB1 transcription factor promotes immune escape in melanoma.
Plaschka M; Benboubker V; Grimont M; Berthet J; Tonon L; Lopez J; Le-Bouar M; Balme B; Tondeur G; de la Fouchardière A; Larue L; Puisieux A; Grinberg-Bleyer Y; Bendriss-Vermare N; Dubois B; Caux C; Dalle S; Caramel J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288462
[TBL] [Abstract][Full Text] [Related]
18. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
Cooper ZA; Juneja VR; Sage PT; Frederick DT; Piris A; Mitra D; Lo JA; Hodi FS; Freeman GJ; Bosenberg MW; McMahon M; Flaherty KT; Fisher DE; Sharpe AH; Wargo JA
Cancer Immunol Res; 2014 Jul; 2(7):643-54. PubMed ID: 24903021
[TBL] [Abstract][Full Text] [Related]
19. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy.
Becker JC; Varki N; Gillies SD; Furukawa K; Reisfeld RA
J Clin Invest; 1996 Dec; 98(12):2801-4. PubMed ID: 8981927
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
